Effectiveness of biologic treatment of psoriasis vulgaris (certolizumab pegol in practice of dermatologist)

Abstract

The work represents the prospective cohort analysis of patients with psoriasis treated with certolizumab pegol (CZP) at the Tula Regional Clinical Dermatovenerologic Dispensary in years 2017–2019, who achieved remission and discontinued CZP and real-time observation of the patients. The patients remained in sustained remission after discontinuation of certolizumab pegol (mean drug-free remission was 42 weeks). Patients who had not responded to systemic therapy prior to CZP treatment demonstrated good response to methotrexate and cyclosporin A, which suggests the modulation of immune response by certolizumab pegol. The obtained results demonstrate that intermittent treatment with certolizumab pegol effiiently controls psoriasis, reduces drug burden.